Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies

Journal of Psychopharmacology

Volumn 20, Issue 4 SUPPL., 2006, Pages 33-40

  Lotrich, Francis E ^a   Bies, Robert R ^b   Smith, Gwenn S ^c   Pollock, Bruce G ^a,b,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Concentration; Neuroimaging; Pharmacogenetics; Population pharmacokinetics

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; NEUROLEPTIC AGENT; PAROXETINE; QUETIAPINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EXPOSURE; DRUG RESPONSE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEUROENDOCRINE SYSTEM; NEUROIMAGING; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; POPULATION PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; TECHNIQUE;

CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; PHARMACOGENETICS; POSITRON-EMISSION TOMOGRAPHY;

EID: 33750087310     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806066044     Document Type: Article

References (53)

1. Amsterdam J D, Fawcett J, Quitkin F M (1997) Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 154: 963-969
2. Bies R R, Gastonguay M R, Coley K C, Kroboth P D, Pollock B G (2002) Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. Am J Geriatr Psychiatry 10: 696-705
3. Bies R R, Muldoon M F, Pollock B G, Manuck S, Smith G, Sale M E (2006) A genetic algorithm based, hybrid machine learning approach to model building. Journal of Pharmacokinetics and Pharmacodynamics 33: 195-221
4. Bies R, Feng Y, Lotrich F E, Kirshner M A, Roose S, Kupfer D J, Pollock B G (2004) Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 44: 1352-1359
5. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C (1999) Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 174: 297-303
6. Booth B P, Gobburu J V S (2003) Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol 43: 1307-1315
7. Burnier M, Schneider M P, Chiolero A, Stubi C, Brunner H R (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19: 335-341
8. Cotler S J, Wartelle C F, Larson A M, Gretch D R, Jensen D M, Carithers R L J (2000) Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 7: 211-217
9. Crabbe J C, Gallaher E J, Cross S J, Belknap J K (1998) Genetic determinants of sensitivity to diazepam in inbred mice. Behav Neurosci 112: 668-677
10. Dennis G C, Soni D, Dehkordi O, Millis R M, James H, West W L, Taylor R E (1999) Analgesic responses to intrathecal morphine in relation to CSF concentrations of morphine-3,beta-glucuronide and morphine-6,beta-glucuronide. Life Sci 64: 1725-1731
11. Ette E I, Williams P J (2004) Population pharmacokinetics II: estimation methods. Ann Pharmacother 38: 1907-1915
12. Ette E I, Sun H, Ludden T M (1998) Balanced designs and longitudinal population pharmacokinetic studies. J Clin Pharmacol 38: 417-423
13. Feng Y, Pollock B G, Ferrell R E, Kimak M, Reynolds C F, Bies R R (2006) Paroxetine: population pharmacokinetics analysis in late-life depression using sparse concentration sampling. Brit J Clin Pharmacol 61: 558-569
14. Feng Y, Pollock B G, Roose S, Kirshner M A, Lotrich F E, Kupfer D J, Bies R R (2003) A mixed effects pharmacokinetic modeling of an age effect on citalopram disposition (abstract). American Association of Pharmaceutical Scientists. Salt Lake City, Utah
15. Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kulni K U, Rao M L (2004) Pharmacokinetics of m-chlorophenylopiperazine after intravenous and oral administration in healthy male volunteers: implications for the pharmacodynamic profile. Pharmacopsychiatry 37: 180-188
16. Finn D A, Roberts A J, Lotrich F, Gallaher E J (1997) Genetic differences in behavioral sensitivity to a neuroactive steroid. J Pharmacol Exp Ther 280: 820-828
17. Gex-Fabry M, Haffen E, Paintaud G, Bizouard P, Sechter D, Bechtel P R, Balant L P (2000) Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation. Ther Drug Monit 22: 701-711
18. Gilles M, Deuschle M, Kellner S, Shams M, Krumm B, Hartter S, Heuser I, Hiemke C (2005) Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 38: 118-121
19. Grasmader K, Verwohlt P L, Kuhn K U, Frahnert C, Hiemke C, Dragicevic A, von Widdern O, Zobel A W, Maier W, Rao M L (2005) Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry 38: 113-117
20. Guentert T W, Banken L, Hilton S, Holford N H (1995) Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol (suppl.) 15: 84S-94S
21. Hung C C, Lin C J, Chen C C, Chang C J, Liou H H (2004) Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 26: 534-540
22. Judson R (2003) Using multiple drug exposure levels to optimize power in pharmacogenetic trials. J Clin Pharmacol 43: 816-824
23. Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R S, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
24. Lotrich F E, Bies R, Muldoon M, Manuck S B, Smith G S, Pollock B G (2004) Neuroendocrine response to intravenous citalopram in healthy control subjects: Pharmacokinetic influences. Pyschopharmacol 178: 268-275
25. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G (2002) The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12: 3-9
26. Lunn D J, Best N, Thomas A, Wakefield J, Spiegelhalter D (2002) Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodynam 29: 271-307
27. Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N, Higuchi S (2000) CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55: 821-825
28. Mamo D, Kapur S, Shammi C M, Papatheodorou G, Mann S, Therrien F, Remington G (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161: 818-825
29. Marder S R (1994) The role of dosage and plasma levels in neuroleptic relapse prevention. Acta Psychiatr Scand 382: 25-27
30. Mayberg H S (2002) Modulating limbic-cortical circuits in depression: targets of antidepressant treatments. Semin Clin Neuropsychiatry 7: 255-268
31. Meyer J H, Wilson A A, Ginovart N, Goulding V, Hussey D, Hood K, Houle S (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry. 158(11): 1843-1849
32. Meyer J H, Wilson A A, Sagrati S, Hussey D, Carella A, Potter W Z, Ginovart N, Spencer E P, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835
33. Murphy G M J, Kremer C, Rodrigues H E, Schatzberg A F (2003) Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830-1835
34. Nakade S, Nishibori A, Okamoto H, Higuchi S (2004) Statistical evaluation of clinical trial design for a population pharmacokinetic study - a case study. Drug Metab Pharmacokinet 19: 381-389
35. Nebes R, Pollock B G, Meltzer C C, Saxton J A, Houck P R, Halligan E M, DeKosky S T (2005) Serum anticholinertic activity, white matter hyperintensities and cognitive performance. Neurology 65: 1487-1489
36. Pollock B G, Ferrell R E, Mulsant B H, Mazumdar S, Miller M, Sweet R A, Davis S, Kirshner M A, Houck P R, Stack J A, Reynolds C F, Kupfer D J (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacol 23: 587-590
37. Preskorn S H (1997) Recent dose-effect studies regarding antidepressants. In Balant L P, Benitez J, Dahl S G, Gram L F, Pinder R M, Potter W Z (eds), Clinical Pharmacology in Psychiatry: Finding the Right Dose of Psychotropic Drugs. European Communities, Belgium, pp. 43-62.
38. Rabiner E A, Bhagwagar Z, Gunn R N, Sargent P A, Bench C J, Cowen P J, Grasby P M (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 158: 2080-2082
39. Racine-Poon A (1985) A Bayesian approach to nonlinear random effects models. Biometrics 41: 1015-1023
40. Rao M L, Deister A, Laux G, Staberock U, Hoflich G, Moller H J (1996) Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry 29: 97-102
41. Romberg R R, Olofsen E, Bijl H, Taschner P E, Teppema L J, Sarton E Y, van Kleef J W, Dahan A (2005) Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102: 522-530
42. Sasongko L, Link J M, Muzi M, Mankoff D A, Yang X, Collier A C, Shoner S C, Unadkat J D (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77: 503-514
43. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K (2003) Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37: 433-451
44. Schneider L S, Ismail M S, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan J M, Sultzer D L, Tariot P N (2003) Clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bull 29: 57-72
45. Sheiner L B, Beal S L (1980) Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8: 553-571
46. Smith G S, Lotrich F E, Malhotra A K, Lee A, Ma Y, Kramer E, Gergersen P, Eidelberg D, Pollock B G (2004) The effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacol 29: 2226-2234
47. Stein M A, Waldman I D, Sarampote C S, Seymour K E, Robb A S, Conlon C, Kim S-J, Cook E H J (2005) Dopamine transporter genotype and methylphenidate dose-response in children with ADHD. Neuropsychopharmacol 30: 1374-1382
48. Tasker T C, Kaye C M, Zussman B D, Link C G (1989) Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand (suppl.) 350: 152-155
49. Tauscher J, Jones C, Remington G, Zipursky R, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7: 317-321
50. Tauscher J, Kapur S (2001) Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15: 671-678
51. Wahlby U, Bouw M, Jonsson E, Karlsson M (2002) Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodynam 29: 251-269
52. Wahlby U, Jonsson E N, Karlsson M O (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodynam 28: 231-252
53. Zhang L, Beal S L, Sheiner L B (2003) Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodynam 30: 405-416